糖尿病患者体内的甲基乙二醛和晚期糖基化终产物——我们目前所了解的情况及尚待完善的环节
Methylglyoxal and Advanced Glycation End Products in Patients with Diabetes - What We Know so Far and the Missing Links.
作者信息
Groener Jan Benedikt, Oikonomou Dimitrios, Cheko Ruan, Kender Zoltan, Zemva Johanna, Kihm Lars, Muckenthaler Martina, Peters Verena, Fleming Thomas, Kopf Stefan, Nawroth Peter P
机构信息
Department Medicine I and Clinical Chemistry, University of Heidelberg, Heidelberg, Germany.
Molecular Medicine Partnership Unit, European Molecular Biology Laboratory and University of Heidelberg, Heidelberg, Germany.
出版信息
Exp Clin Endocrinol Diabetes. 2019 Sep;127(8):497-504. doi: 10.1055/s-0043-106443. Epub 2017 Apr 13.
Hyperglycemia explains the development of late diabetic complications in patients with diabetes type 1 and type 2 only partially. Most therapeutic efforts relying on intensive glucose control failed to decrease the absolute risk for complications by more than 10%, especially in patients with diabetes type 2. Therefore, alternative pathophysiological pathways have to be examined, in order to develop more individualized treatment options for patients with diabetes in the future. One such pathway might be the metabolism of dicarbonyls, among them methylglyoxal and the accumulation of advanced glycation end products. Here we review currently available epidemiological data on dicarbonyls and AGEs in association with human diabetes type 1 and type 2.
高血糖仅部分解释了1型和2型糖尿病患者晚期糖尿病并发症的发生发展。大多数依赖强化血糖控制的治疗措施未能将并发症的绝对风险降低超过10%，尤其是在2型糖尿病患者中。因此，必须研究其他病理生理途径，以便未来为糖尿病患者开发更个性化的治疗方案。其中一条途径可能是二羰基化合物的代谢，包括甲基乙二醛以及晚期糖基化终产物的积累。在此，我们综述目前关于二羰基化合物和晚期糖基化终产物与1型和2型人类糖尿病相关的流行病学数据。
Zotero 插件